Cargando…

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten−/− melanoma

Phosphoinositide-dependent kinase-1 (PDK-1) is a serine/threonine protein kinase that phosphorylates members of the conserved AGC kinase superfamily, including AKT and PKC, and is implicated in important cellular processes including survival, metabolism and tumorigenesis. In large cohorts of nevi an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scortegagna, Marzia, Ruller, Chelsea, Feng, Yongmei, Lazova, Rossitza, Kluger, Harriet, Li, Jian-Liang, De, Surya K, Rickert, Robert, Pellecchia, Maurizio, Bosenberg, Marcus, Ronai, Ze’ev A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955742/ https://www.ncbi.nlm.nih.gov/pubmed/24037523 http://dx.doi.org/10.1038/onc.2013.383

Ejemplares similares

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in (V600E)BRAF Harboring Melanoma Cells
por: Jin, Hui, et al.
Publicado: (2013)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Siah2 control of T-regulatory cells limits anti-tumor immunity
por: Scortegagna, Marzia, et al.
Publicado: (2020)

The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities
por: Qi, Jianfei, et al.
Publicado: (2010)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
por: Qin, Yifei, et al.
Publicado: (2021)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010)

Spitz nevi and Spitzoid melanomas - Exome sequencing and comparison to conventional melanocytic nevi and melanomas
por: Lazova, Rossitza, et al.
Publicado: (2017)

VEGF blockade enhances the antitumor effect of BRAF(V) (600E) inhibition
por: Comunanza, Valentina, et al.
Publicado: (2016)

Response and resistance to BRAF(V600E) inhibition in gliomas: Roadblocks ahead?
por: Capogiri, Monica, et al.
Publicado: (2023)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015)

Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation
por: Megías, Javier, et al.
Publicado: (2022)

Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy
por: Lau, Eric, et al.
Publicado: (2015)

Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma
por: Busch, Elena, et al.
Publicado: (2020)

Fine Tuning of the UPR by the Ubiquitin Ligases Siah1/2
por: Scortegagna, Marzia, et al.
Publicado: (2014)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
por: Sen, Shiraj, et al.
Publicado: (2020)

Remarkable response of BRAF(V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report
por: Li, Hong-Shuai, et al.
Publicado: (2021)

Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial
por: Tian, Jun, et al.
Publicado: (2023)

LGG-23. OUTCOMES UTILIZING BRAF INHIBITION MONOTHERAPY IN BRAF(V600E) MUTATED PEDIATRIC LOW GRADE GLIOMAS
por: McThenia, Sheila, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
por: Hu, W, et al.
Publicado: (2013)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis
por: Nelson, David S., et al.
Publicado: (2019)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
por: Munjapara, Vasu, et al.
Publicado: (2022)

(V600E)BRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells
por: Jiménez-Mora, Eva, et al.
Publicado: (2021)

48218 Preclinical modeling of BRAF(V600E)/PTEN-/- melanoma leptomeningeal disease (LMD) to assess intrathecal checkpoint blockade
por: Guerrieri, Renato A., et al.
Publicado: (2021)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
por: DiPeri, Timothy P., et al.
Publicado: (2022)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Rewired Notch/p53 by Numb’ing Mdm2
por: Kim, Hyungsoo, et al.
Publicado: (2018)

CALPA-IN NF1
por: Lazar, Ikrame, et al.
Publicado: (2018)

PRMT5 function and targeting in cancer
por: Kim, Hyungsoo, et al.
Publicado: (2020)

The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium
por: Grego-Bessa, Joaquim, et al.
Publicado: (2016)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_poeppke7r34j5mcdn20n4p8dgr